// App-Quantinova.ai

: Health-Related Quality of Life in Adults with B-Cell Precursor Acute Lymphoblastic Leukemia and Minimal Residual Disease Treated with Blinatumomab

Researchers

Presenter

  • Ralf C Bargou

Principal Investigators

  • Gerhard Zugmaier

  • Massimiliano Bonifacio

  • Carlos Graux

  • Christoph Faul

  • Max S. Topp

  • Qui Tran

  • Xinke Zhang

  • Nicola Goekbuget

Medical Centers

  • Comprehensive Cancer Center Mainfranken, Universitaetsklinikum Wuerzburg, Wuerzburg, Germany

  • Amgen Research GmbH, Munich, Germany

  • Department of Medicine, Section of Hematology, University of Verona, Verona, Italy

  • Université Catholique de Louvain, CHU UCL Namur (Godinne),Yvoir,Belgium

  • University Hospital and Comprehensive Cancer Center Tübingen, Universitätsklinikum Tübingen,Tübingen,Germany

  • Medizinische Klinik und Poliklinik II, Universitatsklinikum Wurzburg, Wurzburg, Germany

  • Global Biostatistical Science, Amgen Inc., Thousand Oaks, CA

  • Global Health Economics, Amgen Inc., Thousand Oaks, CA

  • Department of Medicine II, University Hospital Freiburg, Freiburg, Germany

Locations

  • Germany

  • Italy

  • Belgium

  • United States

Companies

  • AMGEN Research (Muni

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

  • Central Nervous System (CNS)

  • Gastroenterology (GU)

  • Oncology (ONC)

  • Pulmonary/Respiratory Diseases

Disease

  • Acute lymphoblastic leukemia

  • Constipation

  • Insomnia

  • Dyspnea

Biomarkers

  • Breakpoint Cluster Region

Drug/Treatment

  • Blinatumomab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • EORTC

  • NCT01207388

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved